Insulina aspart en terapia con perfusión subcutánea continua de insulina

1993, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus, N Engl J Med, 329, 977, 10.1056/NEJM199309303291401 2002, The effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus, JAMA, 287, 2563, 10.1001/jama.287.19.2563 Hirsch, 2005, Insulin analogues, N Engl J Med, 352, 174, 10.1056/NEJMra040832 Anderson, 1997, Reduction of postprandial hyperglycemia and frequency of hypoglycaemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group, Diabetes, 46, 265, 10.2337/diabetes.46.2.265 Home, 2000, Insulin aspart vs. human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: a randomized controlled trial, Diabet Med, 17, 762, 10.1046/j.1464-5491.2000.00380.x Heller, 2004, Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with Type 1 diabetes, Diabet Med, 21, 769, 10.1111/j.1464-5491.2004.01244.x Rave, 2006, Advantage of premeal-injected insulin glulisine compared with regular human insulin in subjects with type 1 diabetes, Diabetes Care, 29, 1812, 10.2337/dc06-0383 Homko, 2003, Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects, Diabetes Care, 26, 2027, 10.2337/diacare.26.7.2027 Hedman, 2001, Direct comparison of insulin lispro and aspart shows small differences in plasma insulin profiles after subcutaneous injection in type 1 diabetes, Diabetes Care, 24, 1120, 10.2337/diacare.24.6.1120 Poulsen, 2005, Precipitation of insulin products used for continuous subcutaneous insulin infusion, Diabetes Technol Ther, 7, 142, 10.1089/dia.2005.7.142 Apidra [prescribing information]. Bridgewater, NJ: Sanofi-Aventis, US LLC; 2009. Zinman, 1997, Insulin lispro in CSII: results of a double-blind crossover study, Diabetes, 46, 440, 10.2337/diabetes.46.3.440 Hirsch, 2005, Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII, Diabetes Care, 28, 533, 10.2337/diacare.28.3.533 Hildebrandt, 1986, Subcutaneous insulin infusion: change in basal infusion rate has no immediate effect on insulin absorption rate, Diabetes Care, 9, 561, 10.2337/diacare.9.6.561 Petersen, 2010, Pharmacokinetics following continuous subcutaneous insulin infusion of insulin aspart with or without initial subcutaneous bolus, Diabetes, Obesity and Metabolism, 12, 334, 10.1111/j.1463-1326.2009.01168.x Bode, 2011, Comparison of pharmacokinetic properties, physicochemical stability, and pump compatibility of a rapid-acting insulin analogues- aspart, lispro and glulisine, Endocrine Practice, 17, 271, 10.4158/EP10260.RA Cobry, 2010, Timing of meal insulin boluses to achieve optimal postpradial glycemic control in patients with type 1 diabetes, Diabetes Technol Ther, 12, 173, 10.1089/dia.2009.0112 Hoogma, 2006, Safety of insulin glulisine when given by continuous subcutaneous insulin infusion using and external pump in patients with type 1 diabetes, Horm Metab Res, 38, 429, 10.1055/s-2006-944549 Dreyer, 2005, Efficacy and safety of insulin glulisine in patients with type 1 diabetes, Horm Metab Res, 37, 702, 10.1055/s-2005-870584 Bartolo, 2008, Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes, Diabetes Technol Ther, 10, 495, 10.1089/dia.2008.0013 Weinzimer, 2008, Insulin Aspart Pediatric Pump Study Group. A randomized trial comparing continuous subcutaneous insulina infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes, Diabetes Care, 31, 210, 10.2337/dc07-1378 Plank, 2002, A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes, Diabetes Care, 25, 2053, 10.2337/diacare.25.11.2053 Bode, 2002, Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study inn type 1 diabetes, Diabetes Care, 25, 439, 10.2337/diacare.25.3.439 Heise, 2007, Insulin glulisine: a faster onset of action compared with insulin lispro, Diabetes Obes Metab, 9, 746, 10.1111/j.1463-1326.2007.00746.x Brange, 1997, Toward understanding insulin fibrillation, J Pharm Sci, 86, 517, 10.1021/js960297s Poulsen, 2007, Precipitation of insulin aspart and insulin glulisine products used for continuous subcutaneous insulin infusion, Diabetes Technol Ther, 9, 75, 10.1089/dia.2006.0054 Senstius, 2007, In vitro stability of insulin aspart in simulated continuous subcutaneous insulin infusion using a Minimed 508 insulin pump, Diabetes Technol Ther, 9, 75, 10.1089/dia.2006.0041 Senstius, 2007, Comparison of in vitro stability of insulin aspart and glulisine during simulated use in insulin pumps, Diabetes Technol Ther, 9, 517, 10.1089/dia.2007.0233 DeFilippis, 2006, In vitro stability of insulin lispro in continuous subcutaneous insulin infusion, Diabetes Technol Ther, 8, 358, 10.1089/dia.2006.8.358 Humalog [prescribing information]. Indianápolis, IN: Eli Llilly & Company; 2009. Apidra [prescribing information]. NJ: Sanofi-Aventis. US LLC; 2009. NovoLog [package insert]. Princeton, NJ: Novo Nordisk A/S; 2010. Wolpert, 2002, Metabolic decompensation in pump users due to lispro insulin precipitation, BMJ, 324, 1253, 10.1136/bmj.324.7348.1253 Kerr, 2008, Laboratory-based non-clinical comparison of occlusion rates using three rapid-acting insulin analogs in continuous subcutaneous insulin infusion catheters using low flow rates, J Diabetes Sci Technol, 2, 450, 10.1177/193229680800200314 Van Bon, 2011, Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial, Diabetes Technol Ther, 13, 607, 10.1089/dia.2010.0224 Jovanovic, 2011, Letter written in response to van Bon et al: “Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial”, Diabetes Technol Ther, 13, 869, 10.1089/dia.2011.0122